Diasorin SpA sold its Flow Cytometry and Imaging (FCI) business unit to Cytek Biosciences Inc. for $46.5 million in cash. That’s quite a drop from the $75 million price Diasorin subsidiary Luminex Corp. paid Milleporesigma for the FCI assets in 2018. The companies expect the sale to close within 30 days.
Consolidation in diagnostics continues apace, with Diasorin SpA set to take over Luminex Corp. in an all-cash deal that values the multiplex diagnostics and molecular testing specialist at $1.8 billion. At $37 per share, the price is a 23% premium to the Luminex (NASDAQ:LMNX) share price on Feb. 23, which is when rumors of the acquisition began to circulate, and 12% above the close last Friday, April 8.
